QuantuMDx: Jonathan O'Halloran, Neil Butler, Elaine Warburton, John Burn
QuantuMDx announced the appointments of Jonathan O'Halloran as CEO and Neil Butler as chairman of the board as the company begins its transition to commercialization.
A cofounder and former CSO of the firm, O'Halloran invented many of its proprietary technologies. He has a background in genetics and genomics and has been focusing on tuberculosis and antimicrobial resistance for the past 12 years.
QuantuMDx appointed Neil Butler to its board as a non-executive director in July 2019. He also serves on the boards of Nidor Dx, Radisens, and Spectromics and previously served as chair and non-executive director for Binx Health and Genomic Vision.
QuantuMDx said its CEO and Cofounder Elaine Warburton will move into the role of non-executive director and continue to support QuantuMDx in an ambassadorial role, including with key strategic projects. John Burn will step back as chairman, a role he had undertaken upon the company's inception in 2008, and become vice-chairman of the board of directors.